ストックスクリーナーアプリを入手
4.98
5.51%
0.26
前日終値:
$4.72
開ける：
$4.96
24時間の取引高:
48,545
Relative Volume:
0.70
時価総額：
$22.80M
収益：
$27.37M
当期純損益:
$-54.66M
株価収益率:
-0.2611
EPS:
-19.0729
ネットキャッシュフロー:
$-49.98M
1週間 パフォーマンス:
-20.19%
1か月 パフォーマンス:
+3.32%
6か月 パフォーマンス:
-59.84%
1年 パフォーマンス:
-43.98%
1日の値動き範囲:
$4.5293
$5.28
1週間の範囲:
$4.5293
$6.46
52週間の値動き範囲:
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
名前
Nextcure Inc
セクター
電話
240-399-4900
住所
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
4.98 | 22.80M | 27.37M | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-03-05 | アップグレード | Truist | Hold → Buy |
| 2021-01-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-07-16 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-07-13 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-13 | ダウングレード | SunTrust | Buy → Hold |
| 2020-06-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-03-24 | 開始されました | The Benchmark Company | Buy |
| 2020-03-02 | 開始されました | ROTH Capital | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-05 | 開始されました | Needham | Buy |
| 2019-11-26 | 開始されました | BTIG Research | Buy |
| 2019-07-09 | 開始されました | BofA/Merrill | Buy |
| 2019-06-03 | 開始されました | Morgan Stanley | Overweight |
| 2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Nextcure Inc (NXTC) 最新ニュース
Two filers report the same passive stake in NextCure (NXTC), with shared voting power. - Stock Titan
About 90% of votes cast backed a share split. NextCure (NXTC) now asks a court to validate it. - Stock Titan
NextCure (Nasdaq:NXTC)Stock Analysis - Simply Wall Street
NextCure Ends Beltsville Lease to Cut Operating Costs - TipRanks
About 30,000 sq ft of lab as NextCure (NXTC) exits Maryland site—what it paid to leave early - Stock Titan
NextCure Enters Into Ninth Amendment To Lease Agreement And Vacates Premises At 8000 Virginia Manor Road - marketscreener.com
NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - kalkine.ca
NextCure (NXTC) Q2 2026 Earnings: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
NextCure (NASDAQ: NXTC) plans Avere merger backed by $820M raise - Stock Titan
NextCure (NXTC) Share-Price Review: Declines 11.15% to $6.85 at the Close; Current Range Read: the Near-Term Reference Band Stretches From $6.51 to $7.19 under the Current SnapshotExtension Target - vinanet.vn
Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan
NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan
Nextcure Stock Price Forecast. Should You Buy NXTC? - StockInvest.us
NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan
Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks
Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com India
Simcere Zaiming sells $184,800 of NextCure stock - Investing.com
Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com Canada
Simcere Zaiming sells $184,800 of NextCure stock - Investing.com
Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan
RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East
RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger - Kalkine Media
NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine
NextCure - thepharmaletter.com
NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan
Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - Nasdaq
XCELLON BIOLOGICS: CO ACQUIRES GMP MANUFACTURING FACILITY FROM NEXTCURE - Moomoo
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - BioSpace
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingView
NextCure, Inc. Q2 2026: Net income $(14.9)M, EPS $(2.80) — 10-Q Summary - TradingView
NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock Titan
NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock Titan
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - Barchart.com
NextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4 - Stock Titan
Form 4 NextCure Inc For: 4 August By Investing.com - Investing.com UK
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares - Investing.com
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com - Investing.com India
Form 4 NextCure Inc For: 4 August By Investing.com - Investing.com Nigeria
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com - Investing.com Australia
Nextcure Inc (NXTC) 財務データ
収益
当期純利益
現金流量
EPS
Nextcure Inc (NXTC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 31 '26 |
Buy |
4.94 |
36,303 |
179,375 |
722,419 |
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 30 '26 |
Buy |
4.93 |
292,850 |
1,444,746 |
686,116 |
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 29 '26 |
Buy |
5.00 |
3,410 |
17,050 |
393,266 |
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 28 '26 |
Buy |
4.95 |
6,400 |
31,677 |
389,856 |
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 27 '26 |
Buy |
5.00 |
7,798 |
38,985 |
383,456 |
3.09%
0.72%
大文字化:
|
ボリューム (24 時間):